Insmed price target raised to $166 from $162 at Morgan Stanley

Morgan Stanley raised the firm’s price target on Insmed (INSM) to $166 from $162 and keeps an Equal Weight rating on the shares. Management’s $1B or more 2026 Brinsupri revenue guidance was broadly in line with expectations, but commentary around potential U.S. addressable market expansion “underscores upside beyond initial expectations,” says the analyst, who sees 2026 as “a critical year for improving visibility.”